Latest From Biotech Now

BIO Investor Forum Closing Plenary: How Fragile is the Biotech Rally After Five Positive Years?


Last week’s 13th Annual BIO Investor Forum closed on Wednesday with a plenary session asking, “How fragile is the biotech rally after five positive years?” Moderated by Todd Foley, Managing Director, MPM Capital, the panel included: Rachel King, CEO, GlycoMimetics and Chair, BIO Ellen Lubman, VP Strategy and Innovation, Forest Laboratories Vijay Murthy, Director, Ventures and Early Stage Collaborations, AbbVie Michael A. Margolis, RPh, Managing Director, ROTH Capital Partners Doug Fambrough, PhD, CEO, Dicerna Pharmaceuticals Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

A Patient at BIO Investor Forum


“Sir?” The security guard walks to the Partnering desk, slightly confused. “Sir, there’s a man with no badge. He says he’s not registered for the conference. But he says he needs to talk to you.” At BIO events, you can always expect the unexpected. I nod to the guard. “Let him in.” A man. 70s. Stooped; hunched; gnarled. Disheveled. Faded tattoos on his forearms. Yet, a twinkle in his eye and an unexpected motorcycle helmet Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Center for Medicine in the Public Interest Challenges Accuracy of 60 Minutes Cancer Story

scientist, lab

This week, the Center for Medicine in the Public Interest issued a press release criticizing CBS’ “60 Minutes” segment on cancer treatment prices as not just distorted but ‘dead wrong.’ “Featuring physicians that argue that treatment prices are too high does not change the fact that the cost of cancer drugs are about 12 percent of what health insurers spend on cancer or that new cancer drugs actually save health insurers money. Yet insurers are Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Tony Coelho: A Patient Advocate’s Perspective on Paying for Value


Yesterday, Health Affairs published an op-ed by Tony Coelho, Former Member of the U.S. House of Representatives and Chairman of the Partnership to improve patient care, on the benefit of patient-centered outcomes research to better inform medical care, without limiting patients’ and providers’ choices. As Coelho writes, ‘The movement to place greater financial risk on providers in an effort to pay for value rather than volume will have the effect of fundamentally changing the way Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Answering the Call for Cures in Michigan

21st Century Cures Act

This week, the Kalamazoo Gazette published an op-ed on how we can accelerate the discovery, development and delivery of treatments and cures for patients written by Stephen Rapundalo, President and CEO of MichBio, and BIO’s Jim Greenwood. The op-ed highlights the focus of roundtable discussions being held across the country as part of the 21st Century Cures Initiative. The U.S. House of Representatives’ Energy and Commerce Committee launched the initiative – led by Chairman Fred Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,